Trial Profile
A Phase 2a, Open Label, Multicenter Study to Assess the Efficacy and Safety of the Oral AKT Inhibitor GSK2110183 in Subjects With Langerhans Cell Histiocytosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Afuresertib (Primary)
- Indications Langerhans cell histiocytosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors GSK
- 27 Oct 2017 Status changed from active, no longer recruiting to completed.
- 01 Nov 2014 New trial record